• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chronic myelogenous leukemia: a review and update of therapeutic strategies.

作者信息

Garcia-Manero Guillermo, Faderl Stefan, O'Brien Susan, Cortes Jorge, Talpaz Moshe, Kantarjian Hagop M

机构信息

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.

出版信息

Cancer. 2003 Aug 1;98(3):437-57. doi: 10.1002/cncr.11520.

DOI:10.1002/cncr.11520
PMID:12879460
Abstract
摘要

相似文献

1
Chronic myelogenous leukemia: a review and update of therapeutic strategies.慢性粒细胞白血病：治疗策略的综述与更新
Cancer. 2003 Aug 1;98(3):437-57. doi: 10.1002/cncr.11520.
2
Chronic myelogenous leukemia--update and future directions.
Rev Invest Clin. 1994 Apr;Suppl:118-24.
3
NCCN Practice Guidelines for Chronic Myelogenous Leukemia.美国国立综合癌症网络慢性髓性白血病临床实践指南
Oncology (Williston Park). 2000 Nov;14(11A):229-40.
4
[Treatment of chronic myeloid leukemia].[慢性髓性白血病的治疗]
Nouv Rev Fr Hematol (1978). 1993 Jun;35(3):151-4.
5
Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia.当前关于α干扰素在慢性髓性白血病治疗中作用的争议。
Bone Marrow Transplant. 1996 May;17 Suppl 3:S39.
6
[Therapy of chronic myeloid leukemia].[慢性髓性白血病的治疗]
Internist (Berl). 1993 Jun;34(6):542-9.
7
Bone marrow transplantation for chronic myeloid leukaemia.
Bone Marrow Transplant. 1991;7 Suppl 2:62-3.
8
[Chronic myeloid leukemia: current pathogenetic aspects and new therapeutic approaches (a foreign literature review)].
Ter Arkh. 2001;73(12):96-101.
9
Clinical and epidemiologic burden of chronic myelogenous leukemia.慢性粒细胞白血病的临床和流行病学负担
Expert Rev Anticancer Ther. 2004 Feb;4(1):85-96. doi: 10.1586/14737140.4.1.85.
10
[Interferon-alpha therapy in chronic myelogenous leukemia].
Rinsho Ketsueki. 2000 Apr;41(4):275-9.

引用本文的文献

1
18 months follow-up of deep molecular response 4.5 (MR) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China.尼洛替尼治疗新诊断慢性期慢性髓性白血病患者深度分子反应4.5（MR）的18个月随访：一项中国前瞻性多中心研究
Front Med (Lausanne). 2023 Nov 16;10:1267512. doi: 10.3389/fmed.2023.1267512. eCollection 2023.
2
HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis.外泌体通过 miR-145a-5p/USP6/GLS1 轴促进伊马替尼诱导的 K562-R 细胞凋亡。
Cell Death Dis. 2022 Jan 28;13(1):92. doi: 10.1038/s41419-022-04531-3.
3
Comparison of microRNA Expression Profile in Chronic Myeloid Leukemia Patients Newly Diagnosed and Treated by Allogeneic Hematopoietic Stem Cell Transplantation.
初诊慢性髓系白血病患者与接受异基因造血干细胞移植治疗患者的微小RNA表达谱比较
Front Oncol. 2020 Sep 4;10:1544. doi: 10.3389/fonc.2020.01544. eCollection 2020.
4
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR ): The phase 2, multicenter N-Road study.基于早期获得深度分子学应答（MR）的新诊断慢性期慢性髓性白血病患者接受尼洛替尼的最佳治疗策略：Ⅱ期、多中心 N-Road 研究。
Cancer Med. 2020 Jun;9(11):3742-3751. doi: 10.1002/cam4.3034. Epub 2020 Apr 6.
5
First Case of Transformation of Immunoglobulin Heavy Chain Variable-Mutated Chronic Lymphocytic Leukemia Into Chronic Myeloid Leukemia.免疫球蛋白重链可变区突变的慢性淋巴细胞白血病转化为慢性髓性白血病的首例病例。
Ann Lab Med. 2019 Nov;39(6):577-579. doi: 10.3343/alm.2019.39.6.577.
6
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.慢性髓性白血病与弥漫性大B细胞淋巴瘤并存并伴有既往慢性淋巴细胞白血病：一例报告及文献复习
J Med Case Rep. 2018 Mar 11;12(1):64. doi: 10.1186/s13256-018-1612-4.
7
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.深度分子反应是慢性期慢性髓性白血病患者停用伊马替尼后无治疗缓解的预测因素：日本成人白血病研究组-STIM213研究
Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.
8
Pathways to Genome-targeted Therapies in Serous Ovarian Cancer.浆液性卵巢癌的基因组靶向治疗途径
J Nat Sci. 2017 Jul;3(7).
9
New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.印度尼西亚日惹慢性髓性白血病患者中主要B3a2断点BCR-ABL融合基因的BCR基因新遗传变异
Asian Pac J Cancer Prev. 2017 May 1;18(5):1343-1348. doi: 10.22034/APJCP.2017.18.5.1343.
10
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.费城染色体阳性慢性髓性白血病的治疗进展：尼洛替尼的作用
Biologics. 2016 Feb 26;10:23-31. doi: 10.2147/BTT.S67844. eCollection 2016.